VIRICA BIOTECH

We believe that current viral vector optimization technologies fall short because they fail to address a fundamental challenge, innate cellular antiviral defenses. Viral vectors used in gene therapy and vaccine applications trigger these antiviral defenses which prevents optimal production, leading to lower yield, efficiency, and limited scalability. Virica has developed a unique approach to addressing this challenge... Virica has developed a library of Viral Sensitizers (VSE™) that help to reduce these antiviral defenses during production. VSEs alter cellular signaling and dampen antiviral defenses. This unlocks the potential for higher yields, consistent scaleup, and improved critical quality attributes (CQAs) based on application... Our VSEs have been evaluated in over 50 viral vector manufacturing applications across a wide range of cell lines and viral products. VSEs are primarily used to enhance viral titer, and vector quality attributes through scale-up. Virica has developed a..

Also known as: Virica, Virica Biotech Inc.